The book Coronavirus Therapeutics Volume II provides the most comprehensive review on contemporary knowledge on the consequences during the outbreak of Coronavirus. This also describes the clinical features, diagnostic evaluation and management of Coronavirus patients. Using an integrative approach to the understanding of paradigm gap in host-pathogen interaction studies to the management of Coronavirus patients in the Intensive Care Unit to the current challenges for the effective management of Coronavirus pandemic risk factors including diabetes, hypertension, obesity and repercussion on the central and peripheral nervous system.

Key basic and clinical research laboratories from major universities, academic medical hospitals, biotechnology and pharmaceutical laboratories around the world have contributed articles that review present research activity on the role of heat shock proteins in human diseases and importantly project the field into the future. The book is a must read for graduate students. medical students, basic science researchers and postdoctoral scholars in the fields of Cancer Biology, Oncology, Cardiovascular Diseases, Microbiology, Inflammation, Translational Medicine, Clinical Research, Biotechnology, Cell & Molecular Medicine, Pharmaceutical Scientists and Researchers involved in Drug Discovery.

Prof. Dr. Alexzander A. A. Asea is a highly innovative and accomplished world renowned clinical and basic research scientist and visionary executive leader who has exceptional experience spearheading clinical and basic science research, training, education, and commercialization initiatives within top ranked academic biomedical institutes. Prof. Dr. Asea's initial findings studying the effects of Hsp72 on human monocytes lead to the proposal of a novel paradigm that Hsp72, previously known to be an intracellular molecular chaperones, can be found in the extracellular milieu where it has regulatory effects on immuno-competent cells - a term now called chaperokine. Prof. Dr. Alexzander Asea is also President & CEO of NampEVA BioTherapeutics, a company dedicated to providing affordable medicines to patients in emerging nations. Prof. Dr. Asea has authored over 320 scientific publications including peer-reviewed articles, reviews, books, book chapters, editorials, and news headliners in a wide range of biomedical-related disciplines. Prof. Dr. Asea is the Editor-in-Chief of the widely successful book series Heat Shock Proteins (Springer Nature Publishing) and is an editorial board member of numerous scientific peer-reviewed journals. Prof. Dr. Asea is at the University of Toledo College of Medicine and Life Sciences in Toledo, USA.
Dr. Punit Kaur is an expert in onco-proteogenomics, with extensive training and experience in quantitative mass spectrometry imaging, protein chemistry and biomarker discovery. Dr. Kaur's main research focus is on the use of heat-induced nanotechnology in combination with radiotherapy and chemotherapy in the cancer stem cell therapy. Dr. Kaur has published more than 80 scientific articles, book chapters, and reviews, and currently serves as editorial board member for the European Journal of Cancer Prevention and the Journal of Proteomics and Bioinformatics. Dr. Kaur is the Associate Editor of the highly successful Heat Shock Proteins book series by Springer Nature Publishers. Currently, Dr. Kaur is at the University of Toledo College of Medicine and Life Sciences in Toledo, USA.